NCT00211939 is a Phase 4 clinical trial of calcium acetate in Calcinosis, sponsored by Nabi Biopharmaceuticals.

Who is sponsoring NCT00211939?

NCT00211939 is sponsored by Nabi Biopharmaceuticals.

What drugs are being tested in NCT00211939?

Interventions in NCT00211939: calcium acetate, sevelamer, atorvastatin.

What condition does NCT00211939 study?

NCT00211939 studies Calcinosis, Arteriosclerosis, Hyperparathyroidism, Secondary.

Is NCT00211939 still recruiting?

NCT00211939 is currently completed. Last updated 26 December 2007.

Last reviewed 2007-12-26 · How we verify

NCT00211939

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

CARE-2 (Calcium Acetate (PhosLo®)/Sevelamer(Renagel®) Evaluation Study 2)

Completed Phase 4 Last updated 26 December 2007

What this trial tests

Phase 4 trial testing calcium acetate in Calcinosis in 203 participants. Completed in 1 March 2007.

Timeline

1 January 2005

Primary endpoint
1 December 2006

1 March 2007

Quick facts

Lead sponsor	Nabi Biopharmaceuticals
Phase	Phase 4
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	203
Start date	1 January 2005
Primary completion	1 December 2006
Estimated completion	1 March 2007
Sites	1 location across United States

Drugs / interventions tested

calcium acetate (CALCIUM) — full drug profile →
sevelamer — full drug profile →
atorvastatin (atorvastatin) — full drug profile →

Conditions studied

Calcinosis — all drugs for Calcinosis →
Arteriosclerosis — all drugs for Arteriosclerosis →
Hyperparathyroidism, Secondary — all drugs for Hyperparathyroidism, Secondary →

Sponsor

Nabi Biopharmaceuticals — full company profile →

Who can join

18 and older, any sex, with Calcinosis or Arteriosclerosis. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

electron-beam CT coronary artery calcification AGATSTON score
Time frame: change at 12 mo from baseline

Sponsor's own description

The purpose of the study is to evaluate the effects of two phosphate binders, PhosLo and sevelamer, on heart calcification in dialysis patients. The study will use a non-invasive technique, electron beam computed tomography (CT) scanning, to measure calcium in the coronary arteries, the aortic valve, and the mitral valve.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Phosphate binders for preventing and treating chronic kidney disease-mineral and bone disorder (CKD-MBD).
Ruospo M, Palmer SC, Natale P, Craig JC, et al · · 2018 · cited 82× · PMID 30132304 · DOI 10.1002/14651858.cd006023.pub3

Verify or expand the search:

Other recruiting trials for Calcinosis

Currently open trials in the same condition.

NCT06672822 — Intralesional Injection of STS in Treatment of Calcinosis · Phase 2 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00211939 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Nabi Biopharmaceuticals
Last refreshed: 26 December 2007

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00211939.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing